8 | DNA (Deoxyribonucleic Acid)IBA
01/2020
-
01/2004 |
8 | Temozolomide (Temodar)FDA LinkGeneric
01/2019
-
07/2003 |
7 | Pharmaceutical PreparationsIBA
01/2020
-
03/2005 |
5 | Phosphotransferases (Kinase)IBA
12/2022
-
04/2007 |
5 | Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2019
-
01/2013 |
4 | EnzymesIBA
06/2020
-
07/2002 |
4 | Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2017
-
03/2007 |
3 | Proteins (Proteins, Gene)FDA Link
01/2021
-
05/2005 |
3 | Doxorubicin (Adriamycin)FDA LinkGeneric
01/2020
-
06/2013 |
3 | RG7388IBA
01/2019
-
04/2015 |
3 | ProdrugsIBA
01/2019
-
07/2002 |
3 | 8- dibenzothiophen- 4- yl- 2- morpholin- 4- yl- chromen- 4- oneIBA
12/2017
-
05/2006 |
3 | Biomarkers (Surrogate Marker)IBA
03/2016
-
05/2014 |
3 | Cisplatin (Platino)FDA LinkGeneric
04/2015
-
01/2005 |
3 | Topotecan (Hycamtin)FDA LinkGeneric
04/2015
-
07/2003 |
3 | Etoposide (VP 16)FDA LinkGeneric
06/2013
-
05/2006 |
3 | PoisonsIBA
06/2013
-
01/2004 |
2 | Protein Kinases (Protein Kinase)IBA
06/2020
-
12/2017 |
2 | lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
01/2020
-
08/2012 |
2 | DNA-Activated Protein KinaseIBA
01/2020
-
04/2007 |
2 | AZD 6244IBA
01/2019
-
03/2016 |
2 | rucaparibIBA
12/2017
-
09/2017 |
2 | Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2017
-
06/2011 |
2 | Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2017
-
09/2011 |
2 | Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2017
-
09/2011 |
2 | mirdametinibIBA
03/2016
-
01/2013 |
2 | Small Interfering RNA (siRNA)IBA
01/2016
-
12/2008 |
2 | Type I DNA Topoisomerases (Topoisomerase I)IBA
06/2013
-
01/2004 |
2 | Caspase 3 (Caspase-3)IBA
01/2012
-
09/2005 |
2 | Caspase 9IBA
01/2012
-
09/2005 |
2 | ThymidineIBA
07/2009
-
05/2003 |
2 | 3- (4- chlorophenyl)- 3- (4- hydroxy- 3,5- dimethoxybenzyloxy)- 2- propyl- 2,3- dihydroisoindol- 1- oneIBA
10/2006
-
03/2005 |
2 | Cytotoxins (Cytolysins)IBA
07/2003
-
11/2002 |
1 | Mitogen-Activated Protein KinasesIBA
12/2022 |
1 | LigandsIBA
01/2021 |
1 | Topoisomerase InhibitorsIBA
01/2020 |
1 | GlucocorticoidsIBA
01/2019 |
1 | Dexamethasone (Maxidex)FDA LinkGeneric
01/2019 |
1 | RO6839921IBA
01/2019 |
1 | Drug CombinationsIBA
01/2019 |
1 | Coloring Agents (Dyes)IBA
01/2018 |
1 | 4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA
01/2018 |
1 | DNA Repair EnzymesIBA
12/2017 |
1 | erdafitinibIBA
01/2017 |
1 | dactolisibIBA
03/2016 |
1 | Sirolimus (Rapamycin)FDA Link
03/2016 |
1 | MTOR InhibitorsIBA
01/2016 |
1 | SulfatasesIBA
01/2016 |
1 | Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2016 |
1 | TOR Serine-Threonine KinasesIBA
01/2016 |
1 | BIX 02189IBA
01/2016 |
1 | Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
01/2016 |
1 | Messenger RNA (mRNA)IBA
07/2015 |
1 | Tumor Suppressor Protein p14ARF (p14ARF)IBA
04/2015 |
1 | Busulfan (Busulfex)FDA Link
04/2015 |
1 | 1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
06/2013 |
1 | CamptothecinIBA
06/2013 |
1 | KU59403IBA
06/2013 |
1 | 2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA
01/2013 |
1 | alovudineIBA
01/2013 |
1 | Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
08/2012 |
1 | 2- (4- ethylpiperazin- 1- yl)- N- (4- (2- morpholino- 4- oxo- 4H- chromen- 8- yl)dibenzo(b,d)thiophen- 1- yl)acetamideIBA
08/2012 |
1 | Androgen Receptors (Androgen Receptor)IBA
01/2012 |
1 | 1,2-bis(isothiazol-5-yl)disulfaneIBA
01/2012 |
1 | Lysine (L-Lysine)FDA Link
01/2012 |
1 | Histones (Histone)IBA
01/2012 |
1 | NU6102IBA
09/2011 |
1 | Cyclin-Dependent Kinase 2IBA
09/2011 |
1 | Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA
09/2011 |
1 | Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2011 |
1 | Pemetrexed (MTA)FDA Link
07/2009 |
1 | Folic Acid AntagonistsIBA
07/2009 |
1 | NU 3153IBA
07/2009 |
1 | NU2058IBA
05/2009 |
1 | Apoptosis Regulatory ProteinsIBA
12/2008 |